(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $1.435
Utstedt: 14 feb 2024 @ 21:31
Avkastning: 7.32%
Forrige signal: feb 14 - 15:52
Forrige signal:
Avkastning: -3.68 %
Live Chart Being Loaded With Signals
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer...
Stats | |
---|---|
Dagens volum | 0.00 |
Gjennomsnittsvolum | 969 866 |
Markedsverdi | 128.53M |
EPS | $-0.330 ( 2024-05-02 ) |
Neste inntjeningsdato | ( $0 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.890 |
ATR14 | $0.00400 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Tcg Opportunity Iii Gp, Llc | Buy | 1 000 | Common Stock |
2024-04-05 | Tcg Opportunity Iii Gp, Llc | Sell | 44 000 | Common Stock |
2024-04-05 | Column Group Gp, Lp | Buy | 1 000 | Common Stock |
2024-04-05 | Column Group Gp, Lp | Sell | 44 000 | Common Stock |
2024-04-05 | Column Group L P | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
-56.40 |
Last 100 transactions |
Buy: 3 241 050 | Sell: 9 885 031 |
Volum Korrelasjon
NGM Biopharmaceuticals Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
NVCN | 0.959 |
TIOAU | 0.946 |
AVEO | 0.945 |
NTNX | 0.944 |
ADTH | 0.943 |
BNIXU | 0.94 |
MSDA | 0.939 |
ROVR | 0.939 |
BUFF | 0.938 |
NFLX | 0.938 |
10 Mest negative korrelasjoner | |
---|---|
AGFY | -0.958 |
ENNV | -0.956 |
IRBT | -0.954 |
KBNT | -0.948 |
CSSEP | -0.947 |
FWRD | -0.944 |
BIOL | -0.942 |
TCFC | -0.94 |
TBLT | -0.94 |
GOVX | -0.94 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
NGM Biopharmaceuticals Korrelasjon - Valuta/Råvare
NGM Biopharmaceuticals Økonomi
Annual | 2023 |
Omsetning: | $4.42M |
Bruttogevinst: | $2.20M (49.72 %) |
EPS: | $-1.730 |
FY | 2023 |
Omsetning: | $4.42M |
Bruttogevinst: | $2.20M (49.72 %) |
EPS: | $-1.730 |
FY | 2022 |
Omsetning: | $55.33M |
Bruttogevinst: | $49.35M (89.19 %) |
EPS: | $-1.990 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.555 |
Financial Reports:
No articles found.
NGM Biopharmaceuticals
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.